Home › Studies › PRJNA1249224
PRJNA1249224 SRP578167

Microbiome in Trichuris-infected adults, Côte d'Ivoire RCT

Metagenomic Illumina and Nanopore sequencing data of MAC study cohort

408 stool samples from Trichuris spp.-infected adults in Côte d'Ivoire, in a randomized controlled trial of albendazole, ivermectin-albendazole, and moxidectin-albendazole drug therapy. machine-written summary

408 samples · 816 runs · CI · Adult · 2026 · 11.06 Gbp / sample

ENABioProjectSample sheetRegistryDownloadFlag an issue

Sources
✓Sequence archive 3,672✓Abstract / description 816○Full text○Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive3,672 sample values (collection date, country, intervention, intervention detail, location locality, shared setting id, shared setting type, subject id)
✓ Abstract / description816 sample values (health condition, health condition detail)
○ Full textread; no usable statement or table · PMC13503709
○ Supplementary tablesfiles read; no table could be matched to the samples
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention · arms resolved

RNon-antibiotic pharmaceutical given as the study intervention (metformin: 1 people · 1 samplesdrug 1 people · 1 samplesControl / pre-intervention baseline (sample level only): 204 people · 407 samplesno intervention 204 people · 407 samples
randomised to parallel arms

1 people have samples in more than one arm.

Non-antibiotic pharmaceutical given as the study intervention (metformin design randomized_controlled_trial · population gi_infection_or_diarrhoea · Albendazole vs ivermectin-albendazole vs moxidectin-albendazole, RCT phase 3

“randomized controlled trial including 204 Trichuris spp.-infected individuals” — abstract:42209510 (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 country
Age
adult408
Condition
gi_infection_or_diarrhoea408
Country
CI408
Body site
primary408
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)all projects, 1–3 Gbp: 124,983 samples (22 %)all projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 118 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 290 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 11.06 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinalcommunity

204 of 204 people sampled more than once (408 samples; median 2, up to 2 per person) · follow-up median 18 d (max 18 d) · median interval between samples 18 d (time from visit codes mapped to the stated schedule). Schedule stated by the source: “before treatment at baseline (BL) and 2–3 weeks after treatment at follow-up (FU)” (time origin: treatment_start); stated follow-up 21 d.

2929: day 029: day 180 d4 d9 d13 d18 d

Each row is one person (1 shown of 204); dots are samples at days since that person's first sample.

204 adults from 7 villages in Côte d'Ivoire (BioSample 'village'); sampled at baseline and follow-up7 shared settings.

village or community Tiagba · 114 peoplevillage or community Tiagba13706 — member · 2 samples1370613798 — member · 2 samples1379813840 — member · 2 samples1384013854 — member · 2 samples1385413855 — member · 2 samples1385513856 — member · 2 samples1385613858 — member · 2 samples1385814317 — member · 2 samples1431714319 — member · 2 samples1431914320 — member · 2 samples1432014344 — member · 2 samples1434414375 — member · 2 samples1437514379 — member · 2 samples1437914401 — member · 2 samples1440114402 — member · 2 samples1440214403 — member · 2 samples1440314424 — member · 2 samples1442414442 — member · 2 samples1444214452 — member · 2 samples1445214457 — member · 2 samples14457+94
village or community Akakro · 29 peoplevillage or community Akakro4223 — member · 2 samples42234265 — member · 2 samples42654273 — member · 2 samples42734285 — member · 2 samples42854288 — member · 2 samples42884293 — member · 2 samples42934307 — member · 2 samples43074310 — member · 2 samples43104320 — member · 2 samples43204327 — member · 2 samples43274335 — member · 2 samples43354336 — member · 2 samples43364339 — member · 2 samples43394355 — member · 2 samples43554443 — member · 2 samples44434448 — member · 2 samples44484454 — member · 2 samples44544489 — member · 2 samples44894518 — member · 2 samples45185284 — member · 2 samples5284+9
village or community Bekpou · 18 peoplevillage or community Bekpou12286 — member · 2 samples1228613165 — member · 2 samples1316513170 — member · 2 samples1317013182 — member · 2 samples1318213189 — member · 2 samples1318913221 — member · 2 samples1322113242 — member · 2 samples1324213247 — member · 2 samples1324713248 — member · 2 samples1324813251 — member · 2 samples1325113262 — member · 2 samples1326213319 — member · 2 samples1331913324 — member · 2 samples1332413350 — member · 2 samples1335013359 — member · 2 samples1335913360 — member · 2 samples1336013362 — member · 2 samples1336213372 — member · 2 samples13372
village or community Teffredji · 15 peoplevillage or community Teffredji16810 — member · 2 samples1681016824 — member · 2 samples1682416826 — member · 2 samples1682616844 — member · 2 samples1684416888 — member · 2 samples1688817061 — member · 2 samples1706117230 — member · 2 samples1723017403 — member · 2 samples1740317469 — member · 2 samples1746917482 — member · 2 samples1748217487 — member · 2 samples1748717671 — member · 2 samples1767117686 — member · 2 samples1768617718 — member · 2 samples1771818048 — member · 2 samples18048
village or community Yassap A · 12 peoplevillage or community Yassap A10501 — member · 2 samples1050110502 — member · 2 samples1050210506 — member · 2 samples1050610508 — member · 2 samples1050810509 — member · 2 samples1050910585 — member · 2 samples1058510615 — member · 2 samples1061510644 — member · 2 samples1064410740 — member · 2 samples107409570 — member · 2 samples95709648 — member · 2 samples96489788 — member · 2 samples9788
village or community Ahouya · 11 peoplevillage or community Ahouya5826 — member · 2 samples58265844 — member · 2 samples58445902 — member · 2 samples59025923 — member · 2 samples59235931 — member · 2 samples59316108 — member · 2 samples61086110 — member · 2 samples61106111 — member · 2 samples61116117 — member · 2 samples61176204 — member · 2 samples62046240 — member · 2 samples6240
village or community N'Doumikro · 5 peoplevillage or community N'Doumikro128 — member · 2 samples12829 — member · 2 samples2953 — member · 2 samples53542 — member · 2 samples542554 — member · 2 samples554

member · circles are people (pale = no sequenced sample), arrows run donor → recipient and parent → child, curved lines join twins, partners and siblings, squares are shared settings or families without recorded roles. Shown: 7 shared settings. 204 people in the project overall.

How longitudinal and relatedness information is derived

Community composition

No Sandpiper profile for this project's samples yet.

Field coverage
fieldsamplescoverageR1R2R3R4
age_category408 100%
country408 100%408
health_condition408 100%408
subject_id408 100%408
collection_date408 100%408
detailed_location408 100%
health_condition_detail408 100%408
intervention408 100%408
intervention_detail408 100%408
location_locality408 100%408
shared_setting_id408 100%408
shared_setting_type408 100%408
timepoint_label408 100%408
Papers (2)
  • Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria. 2026 PMID 42209510 PMC13503709 own_data
  • Hybrid-metagenomics reveal off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria 2025 own_data
Details
Archive description

The study was aimed at characterizing off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the bacterial gut microbiome via stool samples collected in a randomized-controlled phase 3 trial conducted in Cote d Ivoire in 2021. ClinicalTrials.gov: NCT04726969.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.62. Assay shotgun_dna.

  • host run.host_tax_id · “9606”
  • body site study.description · “bacterial gut microbiome via stool samples”
  • life stage study.description · “randomized-controlled phase 3 trial”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN47883473collection_date2021R10.90biosample.attribute:collection_date2021
SAMN47883473countryCIR10.90sample.attr.geo_loc_nameCote d'Ivoire
SAMN47883473health_conditiongi_infection_or_diarrhoeaR40.50paper.abstract204 Trichuris spp.-infected individuals
SAMN47883473health_condition_detailAll subjects infected with Trichuris spp. (whipworm)R40.50paper.abstract204 Trichuris spp.-infected individuals
SAMN47883473interventionno_interventionR10.90biosample.attribute:timepointtimepoint: baseline
SAMN47883677interventiondrug_therapyR10.80biosample.attribute:armarm: MOX-ALB
SAMN47883473intervention_detailbaseline, before dosing; assigned arm: moxidectin-albendazole combination therapyR10.90biosample.attribute:timepointtimepoint: baseline
SAMN47883677intervention_detailmoxidectin-albendazole combination therapyR10.80biosample.attribute:armarm: MOX-ALB
SAMN47883473location_localityN'DoumikroR10.85biosample.attribute:villageN'Doumikro
SAMN47883473shared_setting_idN'DoumikroR10.85biosample.attribute:villagevillage: N'Doumikro
SAMN47883473shared_setting_typevillage_or_communityR10.85biosample.attribute:villagevillage: N'Doumikro
SAMN47883473subject_id29R10.85biosample.attribute:id29
SAMN47883473timepoint_labelbaselineR10.85sample.attr.timepointbaseline
Sequencing

816 runs over 408 samples · mean 5.69 Gbp per run (median 5.96 Gbp, total 4,642.44 Gbp; 816 runs with a base count) · layout PAIRED 408, SINGLE 408 · platform ILLUMINA 408, OXFORD_NANOPORE 408 · models Illumina NovaSeq 6000 (408), PromethION (408) · 0% of runs with a Sandpiper profile · first public 2026-05-24 – 2026-06-21

Authors (8)

Dommann J first · Sprecher VP · Beisel C · Ballmer D · Hürlimann E · Coulibaly JT · Keiser J · Schneeberger PHH last

Downloads

PRJNA1249224.csv.gz (11.9 KB) · parquet (86.5 KB) — all 408 samples, every field with route and confidence · PRJNA1249224_determinations.csv.gz (29.1 KB) — 4,488 evidence rows

Samples (408 · every field this project has values for · hover a cell for its source)
Loading the sample table…